ArticleJournal of the American Academy of Audiology2026
The Effect of Bisphosphonate Therapy on Hearing and Middle Ear Dysfunction in Pediatric Osteogenesis Imperfecta.
Article in Journal of the American Academy of Audiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteogenesis imperfecta (OI) is a heterogeneous inherited connective tissue disorder characterized by impaired bone matrix formation. Hearing loss is observed in 28 to 65 percent of patients with OI. Most patients with OI experience conductive hearing loss (CHL); however, mixed and sensorineural (SNHL) hearing loss has also been described. Purpose: The primary aim of this retrospective study was to characterize the rates of middle ear dysfunction (MED) and hearing loss (HL) with pediatric OI and investigate the efficacy of bisphosphonate therapy in HL. Research Design: Retrospective chart review of pediatric patients with OI. Study Sample: Pediatric patients with OI treated between January 2000 and January 2021 were included. HL was defined according to pure tone audiometry, while MED was determined by tympanometry at 226 Hz. Patients were categorized by the OI type and considered to be using bisphosphonates if they had been initiated within 1 year prior to testing. Intervention: No direct intervention was performed. Comparisons between bisphosphate use and no bisphosphonate use were explored. Data Collection and Analysis: The chi-square test was utilized for categorical data to investigate whether a significant association with two-by-two variables existed. Results: This study included 144 patients. Of these patients, 12.5 percent had HL. Tympanometry revealed that 25 percent had MED. Additionally, 82.6 percent were currently using bisphosphonates. Across all OI types, no association between current bisphosphonates and HL or MED was observed. However, a subanalysis of patients with type I OI indicated that the absence of MED was statistically associated with current bisphosphonate therapy (p = 0.025). Conclusion: Bisphosphonates are associated with the absence of MED in pediatric patients with type I OI. Because of its mild disease course, bisphosphonates are not commonly used for many patients with type I OI. By reducing MED and its associated comorbidities, our results suggest that bisphosphonate use may confer a significant therapeutic benefit. Clinical Relevance Statement: HL is common in individuals with OI. Our study suggests that initiating bisphosphates at an earlier age may delay middle ear changes that contribute to HL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.